Scientific Collaboration Opportunities

SU2C Catalyst is a new approach to rapidly explore novel uses of medicines, devices and/or diagnostics to accelerate research on cancer prevention, detection ... ... KRAS mutation in colon cancer. Comput Struct Biotechnol J 2022;20:5287-95 ... informational purposes only and SHOULD NOT be relied upon as a substitute ... Expression level of Immunology-Oncology (I-O) related genes, markers or pathways were measured by Oncomine™. Immune Response Research Assay (Cat. No. A32881,. KRAS mutation showed higher radioresistance in vitro. TCGA data showed that the ERK1/2 pathway, phosphatidylinositol I3 kinase (PI3K)/mTOR, p38 MAPK pathway ... UniProt is the world's leading high-quality, comprehensive and freely accessible resource of protein sequence and functional information. ... PDAC. Our research of PDAC expands to many areas, including developing interventions to block the pancreatitis-facilitated neoplasia of oncogenic KRAS ... Dec 16, 2019 ... ... study. "Exciting emerging data about KRAS G12C inhibitors will likely shape our approach to this specific type of KRAS mutation in the near ... study, in an attempt to fill in the informational gap on the effect of ICIs ... These data support the role of KRAS mutations (in particular KRAS exon 2 p. Jan 7, 2025 ... RAS (consisting of a family of genes including KRAS, HRAS, and NRAS) is commonly mutated in cancer. ... For more information, please see our ... A2ML1, ACTB, ACTG1, BRAF, CBL, HRAS, KAT6B, KRAS, LZTR1, MAP2K1, MAP2K2, NF1 ... informational purposes only. CPT coding is the sole responsibility of ...